Background/Aims: The identification of predictive biomarkers for Alzheimer's disease (AD) from urine would aid in screening for the disease, but information about biological and pathophysiological changes in the urine of AD patients is limited. This study aimed to explore the comprehensive profile and molecular network relations of urinary proteins in AD patients. Methods: Urine samples collected from 18 AD patients and 18 age-and sex-matched cognitively normal controls were analyzed by mass spectrometry and semiquantified with the normalized spectral index method. Bioinformatics analyses were performed on proteins which significantly increased by more than 2-fold or decreased by less than 0.5-fold compared to the control (p < 0.05) using DAVID bioinformatics resources and KeyMolnet software. Results: The levels of 109 proteins significantly differed between AD patients and controls. Among these, annotation clusters related to lysosomes, complement activation, and gluconeogenesis were significantly enriched. The molecular relation networks derived from these proteins were mainly associated with pathways of lipoprotein metabolism, heat shock protein 90 signaling, matrix metalloproteinase signaling, and redox regulation by thioredoxin. Conclusion: Our findings suggest that changes in the urinary proteome of AD patients reflect systemic changes related to AD pathophysiology.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common cause of dementia [1] . The main neuropathological changes associated with AD are extracellular accumulation of amyloid-β plaques, intracellular accumulation of neurofibrillary tangles of τ protein, inflammation, and brain atrophy [1] . Unfortunately, no cure currently exists for AD. Recent studies have shown that brain changes associated with AD start more than a decade before the onset of clinical symptoms such as progressive memory deficits [2] [3] [4] [5] . Thus, in order to reduce the incidence and prevalence of AD, it will be necessary to focus on the stage before clinical symptoms appear [6] . Accumulating evidence suggests that systemic metabolic dysfunction such as diabetes, vascular dysfunction, and systemic inflammation underlie the development of AD [7] [8] [9] . These systemic changes also precede the onset of clinical symptoms of the disease. The discovery of a panel of biomarkers that reflect these systemic changes and could therefore predict the development of AD would be valuable for screening those at risk.
Urine is one of the most preferred biofluids for biomarker discovery because urine collection is simple and noninvasive. Moreover, repeated urine sampling from the same individual is easy, as is collection of a sufficient volume for analysis compared to other biofluids [10, 11] . Urine also contains systemic information since approximately 30% of urinary protein originates from plasma via blood filtration, with the remainder coming from the kidneys and the urinary tract [10, 12] . With technological advances in mass spectrometry (MS), MS-based proteomics has been used to identify a large number of proteins belonging to the urinary proteome [11, 13] . While the discovery of predictive biomarkers for AD from urine would be highly beneficial, information regarding biological and pathophysiological changes in the urine of AD patients is currently limited. In the present study, urinary proteomes of AD patients and cognitively normal elderly controls were compared to explore the comprehensive profile and molecular-network relations of the urinary proteome of AD patients.
Materials and Methods
Participants and Classification AD patients were recruited from outpatients of Niigata University Hospital who were diagnosed with the disease based on criteria of the National Institute of Neurological and Communicative Disorders and Stroke AD and Related Disorders Association (NINCDS-ADRDA) and took the Mini-Mental State Examination (MMSE) [14] within a year of urine collection. The clinical characteristics of the AD group are summarized in online supplementary Table 1 (for all online suppl. material, see www.karger.com/doi/10.1159/000496100).
Age-and sex-matched cognitively normal controls (MMSE score > 27) were selected from a subcohort (Sekikawa cohort) of the Murakami cohort, a population-based cohort study that targeted individuals aged between 40 and 74 years living in areas of the northern Niigata Prefecture (Murakami region) [15] . Participants provided urine samples at specific health checkups held by the national health insurance of Japan and underwent the MMSE within a year of urine collection.
Urine Sample Collection and Laboratory Test
Spot urine samples were obtained from participants. No restrictions on diet, drinking, or exercise were required prior to urine sampling. Urinary protein, urinary sugar, and occult blood were checked using urine test strips (Pretest 5bII [Wako, Japan] for AD samples and Hema-Combistix-long [Siemens Healthcare, Japan] for control samples). Urinary albumin and 
Results

Protein Identification by Liquid Chromatography-MS/MS and Semiquantification by SI N
Urine samples were collected from 18 AD patients (8 males and 10 females) and 18 cognitively normal (MMSE > 27 points) controls selected from participants of the Murakami cohort in an age-and sex-matched manner. General characteristics of the participants and the results of general urinalysis are shown in Table 1 .
For AD and control urine samples, 613.2 ± 117.7 and 589.7 ± 87.3 (mean ± SD) proteins were identified, respectively. Of the total of 1,705 unique proteins identified, 382 and 160 proteins were uniquely identified in AD and control groups, respectively, and 1,163 proteins were shared between the 2 groups (Fig. 1a) . For further analysis, 578 proteins identified in at least 9 samples of either group, excluding 28 keratin isoforms, were selected. Of these, 71 and 37 proteins were uniquely identified in AD and control groups, respectively, and 470 Bold text corresponds to proteins that remained significant after FDR correction. MW, molecular weight; FDR, false discovery rate. a Proteins not identified in certain samples were assumed to be at levels under the detection limit and thus were assigned a value that was half of the minimum SI N value (i.e., 0.0001). proteins were shared between the 2 groups (Fig. 1b) . To estimate protein abundance, SI N , a label-free quantification method, was used. Proteins that were not identified in certain samples were assumed to be at levels under the detection limit and thus they were assigned a value that was half of the minimum SI N value (i.e., 0.0001).
Table 2 (continued)
Welch's t test identified 73 proteins that were significantly increased by more than 2-fold and 36 proteins that were significantly decreased by less than 0.5-fold in the AD group compared to the control group (Fig. 1c) . The accession numbers, names, logarithm of the fold change ratio (AD/control) of the average SI N values, and molecular weights of proteins that were significantly increased or decreased are listed in Table 2 . Twenty-four proteins remained significant after false discovery rate correction (bold in Table 2) .
The expression-level correlations of proteins listed in Table 2 were analyzed in the AD group and the control group (online suppl. Tables 2A and B) . Correlations were compared between AD and control groups (online suppl. Table 2C ). Eleven correlations involving proteins (PSAP, RDX, C7, CPVL, LAIR1, GAA, GALNS, BGN, CNTN1, GPRC5C, and MAN1A1) were significant in both the AD group and the control group (online suppl. Table 2D ), and 4 proteins (PSAP, GAA, GALNS, and BGN) were annotated to the lysosome.
Bioinformatics Analysis
To provide a broad overview of the identified proteins in each group, gene ontology (GO) analysis was performed using DAVID. The profiles of both groups had very similar distributions of GO annotations (online suppl. Fig. 1) . To assess the functional significance of signifi- cantly increased or decreased proteins in the AD group, functional annotation clustering analysis with DAVID was performed using the GO database and KEGG pathway. Three annotation clusters related to lysosomes, complement activation, and gluconeogenesis were significantly enriched (Table 3 ; online suppl. Fig. 2 ).
To identify relationships between the molecular network of the urinary proteome and canonical pathway, an "interrelation" network search was performed using KeyMolnet. In the extracted molecular network, 18 pathways scored > 20 and significantly contributed to the extracted network (online suppl. Table 3 ). The 5 pathways with the highest scores were the heat shock protein (HSP) 90 signaling pathway (score 104.424), lipoprotein metabolism (score 86.737), redox regulation by thioredoxin (score 53.188), the matrix metalloproteinase (MMP) signaling pathway (score 45.325), and the tetraspanin signaling pathway (score 45.319) ( Table 4 , upper panel). To extract molecular relations between AD-related molecules and the urinary proteome, a "start points and end points" network search was performed using KeyMolnet. We found that 71 proteins which were significantly increased or decreased in the urine proteome were associated with AD-related molecules directly or via an intermediate molecule (online suppl. Fig. 4) , and 12 pathways significantly contributed to the extracted AD-related network (online suppl. Table 4 ). Of the 12 pathways, 4 of the top 5 were also listed among the top 5 pathways determined in the "interrelation" network search, i.e., lipoprotein metabolism (score 90.350), the HSP90 signaling pathway (score 57.456), the MMP signaling pathway (score, 47.188), and redox regulation by thioredoxin (score 44.021) ( Table 4 , lower panel).
Discussion
With recent advances in MS-based proteomics, urine has been used in biomarker studies of various diseases, not limited to renal and urogenital diseases, but also for non urogenital diseases such as diabetes, osteoarthritis, cardiovascular disease, lung cancer, and other types of cancer [11, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Many AD biomarker studies have used a proteomics approach, with most using CSF and blood but only a few using urine [31, 32] . A comprehensive profile of the urinary proteome is important for urine biomarker discovery [11, 13] . Therefore, in this study, we performed MS-based urine proteomics with label-free quantification, which offers a greater dynamic range and a wider proteome coverage compared to label-based methods [11] , in order to gain a comprehensive view of the urinary proteome of AD patients.
Rank
Pathway Score In this study, we compared the urinary proteome of 18 AD patients and 18 age-and sexmatched cognitively normal elderly individuals. The average number of identified proteins in individual urine samples was 613 and 589 in the AD and control groups, respectively. This is comparable to previous reports [13, 33, 34] . Recent studies have found that systemic changes, such as insulin resistance, atherosclerosis, and increased inflammation underlie the development of AD [7] [8] [9] . Among the proteins significantly increased or decreased in the AD group compared to the control group, proteins related to lysosomes, the complement pathway, and gluconeogenesis were enriched. In the molecular network analysis, canonical pathways of lipoprotein metabolism, HSP90 signaling, MMP signaling, and redox regulation by thioredoxin significantly contributed to the molecular network of the urinary proteome and ADrelated molecules.
Lysosomes are major cellular organelles that digest and recycle all types of intracellular macromolecules and thus play a major role in protein homeostasis [35] . Previous studies have suggested the involvement of impaired lysosomal activity, including lysosomal enzyme malfunction, in the AD brain starting from an early stage of the disease [36] [37] [38] [39] . In the present study, 7 of 11 lysosome-related proteins corresponded to lysosomal hydrolase. Previous studies have also reported increased activity of lysosomal glycohydrolases at the peripheral level in AD patients [40, 41] .
Although most lysosome-related proteins were increased in AD urine, cathepsin L1 (CTSL) was not. Cathepsins are the most abundant lysosomal proteases and they have been implicated in neuronal death in AD patients [42] . Interestingly, CTSL activity is inhibited in the brains of aged animals [43] . Moreover, recent studies have found that CTSL functions as a key protease for the proteolytic processing of proneuropeptides into active neurotransmitters, and thus it is required for normal neurotransmission [44] .
The complement system represents a key inflammatory pathway for the activation and execution of immune responses. Inflammatory responses in the brain are characteristic of AD pathology [45, 46] . Recent studies have also revealed the occurrence of peripheral or systemic inflammation early in the development of AD [47, 48] .
Insulin is a key hormone that inhibits gluconeogenesis, and insulin resistance is a hallmark of type 2 diabetes [49] . Type 2 diabetes can cause mitochondrial dysfunction and promote an inflammatory response similar to that which triggers AD [50] . Epidemiological studies have found that the risk of AD is about 1.5-fold higher among people with diabetes than in the general population [51, 52] . In the current study, we did not have sufficient information regarding the diabetic status of our participants, particularly the control group. However, the enrichment of proteins related to gluconeogenesis in the urine of AD patients is consistent with the known relationship between AD and diabetes.
Another protein listed in Table 2 that might participate in glucose metabolism is insulinlike growth factor-binding protein-3 (IGFBP3). IGFBP3 is a major binding protein of IGF-1 and several studies have reported its association with incident diabetes [53, 54] . Although results are inconsistent, alterations of circulating IGFBP3 levels in AD patients have been reported [55, 56] .
Several recent studies have concluded that intrabrain vascular dysregulation is the earliest and strongest pathologic factor associated with late-onset AD [8, 57] . Atherosclerosis is a leading cause of vascular dysfunction, and it is the result of hyperlipidemia and lipid oxidation [8, 58] . Thioredoxin is a major regulator of the cellular redox system that protects various cells from oxidative stress and is involved in atherogenesis [59] . According to one study, patients with atherosclerosis had an increased level of plasma thioredoxin-1 [60] . MMP are a large family of proteolytic enzymes and they have been implicated in the development and progression of atherosclerosis [61] . HSP90 is a molecular chaperone that prevents protein misfolding and aggregation [62] . HSP90 and HSP70 have been shown to exert their effects on atherosclerosis by influencing LDL metabolism, and the expression of HSP90 in atherosclerotic plaques has been associated with plaque instability [63] .
Another vascular related protein that was significantly increased in AD urine is oxidized low-density lipoprotein receptor 1 (OLR1), which is also known as lectin-like oxidized lowdensity lipoprotein receptor-1 (LOX-1). OLR1/LOX-1 is a marker for atherosclerosis and it is induced by oxidative stress, inflammatory cytokines, and oxidized low-density lipoprotein [64] . Several studies have suggested an association of several SNP within OLR1 with AD [65] .
Expression levels of several proteins in AD urine observed in the present study were inconsistent with previous reports. For example, S100A6 was significantly decreased in AD urine. In the brain, however, S100A6 has been reported to be upregulated in astrocytes of amyotrophic lateral sclerosis patients and in AD patients [66] .
Although some studies have reported that hyperlipidemia is associated with AD pathogenesis, APOC3 was significantly decreased in AD urine. APOC3 is a major component of triglyceride-rich lipoproteins (chylomicrons and very low-density lipoprotein) and a minor component of high-density lipoprotein. Lin et al. [67] reported decreased levels of serum APOC3 with the progression of AD. Recent studies have reported that weight loss is a predictor of AD and may be related to the hypothalamic defects observed in AD patients [68, 69] .
The present study has some limitations worth noting. First, the abundance of urinary proteins was estimated via a semiquantitative method and requires further validation by a quantitative method. Second, information regarding the comorbidities and renal function of participants was limited. Third, this study employed a cross-sectional case-control design. Further validation of our findings with a larger sample size and different populations is warranted. The above information notwithstanding, we were able to demonstrate differences in the urinary proteome of AD patients compared to cognitively normal controls and that the urinary proteome of AD patients reflects systemic changes that underlie AD pathophysiology. Further studies targeting earlier-stage AD patients or population-based prospective studies will help to clarify the potential of urine as a source of biomarkers for early screening of AD.
